Insider trade

Allogene Therapeutics (ALLO)Director sold ~$20K

Deborah M. Messemer, Director at Allogene Therapeutics, sold ~$20K of Allogene Therapeutics shares.

~$20K
Approx. value · 9,136 sh @ $2.18: 158K
Holds after · shares reported

Traded: Dec 9, 2024
Filed: Dec 10, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Dec 5, 2024InsiderDirector sold ~$20K of ALLO shares in the open market
Dec 9, 2024 · this disclosureInsiderDirector sold ~$20K of ALLO shares in the open market

What came next

Jan 21, 2025InsiderOfficer sold ~$48K of ALLO shares in the open market
Feb 3, 2025Insider · 5 peopleInsiders: 5 sales (~$153K)
Feb 18, 2025InsiderDirector sold ~$32K of ALLO shares in the open market
Mar 14, 2025Insider · 2 peopleInsiders: 2 sales (~$102K)

View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Allogene Therapeutics

For Allogene Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALLO page.

Other recent filings by Deborah M. Messemer, Director

The full history of Deborah M. Messemer, Director is on the profile page.

How this filing works

Other disclosures at Allogene Therapeutics

Everything OQRO holds on this company is on its ALLO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO Pro Already have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data